Updated guidance for PAT-DX1 phase 1 clinical study

Preclinical data supports synthetic lethality application

QUARTERLY ACTIVITIES REPORT & 4C

Patrys receives R&D Tax Incentive Refund

AGM Presentation

Patrys Appoints Dr Charmaine Gittleson as Chairman

Quarterly Activities Report and 4C

PAT-DX3 Crosses Blood Brain Barrier in Healthy Animals

PAT-DX1 Engineering Run Update

New Research Grant For Deoxymabs in Metastatic Breast Cancer